Global Immunotherapy Drugs 2016-2020

Description: About Immunotherapy Drugs

Immunotherapy enhances the innate powers of the immune system. The properties of the immune system to fight abnormal cells give immunotherapy drugs the chance of successfully fighting diseases such as cancer, respiratory, infectious, and autoimmune disorders.

The analysts forecast the global immunotherapy drugs market to grow at a CAGR of 11.52% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global immunotherapy drugs market for the period 2015-2020. To calculate the market size, the report considers revenue generated from the sales of immunotherapy drugs used to treat cancer, respiratory, infectious, autoimmune, and inflammatory diseases. It also considers the revenues to be generated from the sales of drugs, which are expected to be launched into the market, along with the decline in revenues from the patent expiries of marketed drugs during the forecast period.

The market is divided into the following segments based on geography:

- Americas
- APAC
- EMEA

The report, Global Immunotherapy Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

- AbbVie Inc.
- Amgen Inc.
- Bristol-Myers Squibb Company (BMS)
- F. Hoffmann-La Roche AG
- Johnson & Johnson Private Ltd.
- Merck & Co. Inc.

Other prominent vendors

- AB Science
- Ablynx
- Acorda Therapeutics
- ADC Therapeutics
- Aduro Biotech
- Advantagene
- Advaxis
- Agensys Inc.
- Agenus Inc.
- Alder Biopharmaceuticals
- AlphaVax
- Altor BioScience
- Antares Pharma
- Antigen Express
- Argos Therapeutics Inc.
- Astellas Pharma
- AstraZeneca
- AVAX Technologies
- Bavarian Nordic
- Baxter
- Biogen
- Biotech Pharmaceutical
- Biothera
- Boehringer Ingelheim
- Can-Fite BioPharma
- Celgene
- Celldex Therapeutics
- Celltrion
- Cel-Sci
- ChemoCentryx
- Chugai Pharmaceutical
- Coherus BioSciences
- CTI BioPharma
- CureVac
- Cytos Biotechnology
- Daiichi Sankyo
- Eisai
- Eli Lilly
- Fortress Biotech
- Galena Biopharma
- Genexine
- Genmab
- Gilead Sciences
- GSK
- GlobImmune
- Gradalis
- Heat Biologics
- Hospira
- Idera
- Immatics
- ImmunoCellular Therapeutics
- Immunomedics
- ImmuPharma
- ImmuPharma
- Incyte
- Inovio Pharmaceuticals
- Intas Pharmaceuticals
- Invion
- ISA Pharmaceuticals
- Janssen Biotech
- Juvaris Biotherapeutics
- KaloBios Pharmaceuticals
- Kyowa Hakko Kirin
- Lexicon Pharmaceuticals
- MedImmune
- Morphotek
- Neovii Biotech
- Northwest Biotherapeutics
- Novartis
- NovaRx
- Novo Nordisk
- OncoMed Pharmaceuticals
- Oncothyreon
- Oncovir Inc.
- Opera Therapeutics Inc.
- Oxford BioMedica
- Pfizer
- Prima BioMed
- Principia
- Progenics
- Provectus Biopharmaceuticals
- Regeneron
- Sandoz
- Sanofi
- Santarus
- Seattle Genetics
- Sotio
- Spectrum Pharmaceuticals
- Takeda
- TG Therapeutics
- Transgene
- UbiVac
- UCB
- Vaccinex
- Vaccinogen
- Vaxon Biotech
- Vertex Pharmaceuticals
- Vical
- Vitae Pharmaceuticals
- XBiotech

Market drivers
- Growing prevalence of cancer and autoimmune diseases
- For a full, detailed list, view the full report

Market challenges
- Patent expiries of top-selling drugs
- For a full, detailed list, view the full report

Market trends
- Increase in awareness programs
- For a full, detailed list, view the full report

Key questions answered in this report
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?
PART 05: Overview: Immunotherapy
- Types of immunotherapy
- Key events
- Reimbursement policies
- Orphan drug designation and regulatory approvals

PART 06: Pipeline portfolio
- Anticipated number of immuno-oncology pipeline assets with single and multiple indications by 2020

PART 07: Market landscape
- Market overview
- Market size and forecast
- Five forces analysis

PART 08: Market segmentation by type of immunotherapy
- mAbs
- Immune checkpoint inhibitors
- Vaccines
- Non-specific immunotherapies

PART 09: Market segmentation by therapy area

PART 10: Geographical segmentation
- Global immunotherapy drugs market by geographical segmentation 2015-2020
- Immunotherapy drugs market in Americas
- Immunotherapy drugs market in EMEA
- Immunotherapy drugs market in APAC

PART 11: Market drivers
- Growing prevalence of cancer and autoimmune diseases
- Rise in older population
- Increase in demand for mAbs
- Patient assistance programs
- Promising pipeline

PART 12: Impact of drivers

PART 13: Market challenges
- Patent expiries of top-selling drugs
- High costs of biologicals
- Poor diagnosis and screening
- Adverse effects
- Stringent regulations

PART 14: Impact of drivers and challenges

PART 15: Market trends
- Increase in awareness programs
- Emergence of targeted and combination therapies
- Emergence of biosimilars
- Strategic alliances
- Expected entry of novel vaccines

PART 16: Vendor landscape
- Competitive scenario
- Market share analysis 2015
- F. Hoffmann-La Roche
- AbbVie
- Johnson & Johnson
- Merck
- Amgen
- BMS
PART 17: Appendix
- List of abbreviations

PART 18: About the Author

List of Exhibits

Exhibit 01: Product offerings
Exhibit 02: Types of immunotherapy
Exhibit 03: Key events in discovery and approvals of immunotherapy drugs
Exhibit 04: Immunotherapy drugs approved by US FDA in 2015
Exhibit 05: US FDA orphan drug designations and approvals list for immunotherapy drugs
Exhibit 06: EU orphan drug designations and approvals list for immunotherapy drugs
Exhibit 07: Phase III pipeline molecules for mAbs
Exhibit 08: Phase II pipeline molecules for mAbs
Exhibit 09: Phase I pipeline molecules for mAbs
Exhibit 10: Pipeline molecules for immune checkpoint inhibitors
Exhibit 11: Phase III pipeline molecules for vaccines
Exhibit 12: Phase II pipeline molecules for vaccines
Exhibit 13: Phase I pipeline molecules for vaccines
Exhibit 14: Near-launch immuno-oncology pipeline assets
Exhibit 15: Global immunotherapy drugs market 2015-2020 ($ billions)
Exhibit 16: Factors influencing global immunotherapy drugs market
Exhibit 17: Challenges faced by US immunologists while prescribing immunotherapy drugs 2015
Exhibit 18: SWOT analysis of global immunotherapy drugs market
Exhibit 19: Five forces analysis
Exhibit 20: Market segmentation by type of immunotherapy drug
Exhibit 21: Timeline of mAbs approval for cancer by US FDA
Exhibit 22: Timeline of mAbs approval for autoimmune, respiratory, and ophthalmic diseases by US FDA
Exhibit 23: Global mAbs market 2015-2020 ($ billions)
Exhibit 24: Key drivers and challenges of global monoclonal antibodies drugs market
Exhibit 25: Top vendor offerings in global mAbs market
Exhibit 26: Global immune checkpoint inhibitors market 2015-2020 ($ billions)
Exhibit 27: Key driver and challenge for global immune checkpoint inhibitors market
Exhibit 28: Top vendor offerings in global immune checkpoint inhibitors market
Exhibit 29: Global vaccines market 2015-2020 ($ billions)
Exhibit 30: Segmentation of global vaccines market by application 2015
Exhibit 31: Key drivers and challenges of global vaccines market
Exhibit 32: Top vendor offerings in global vaccines market
Exhibit 33: Global non-specific immunotherapies market 2015-2020 ($ billions)
Exhibit 34: Key drivers and challenges of global non-specific immunotherapies market
Exhibit 35: Top vendor offerings in global non-specific immunotherapies market
Exhibit 36: Segmentation of global immunotherapy drugs market by type of immunotherapy 2015
Exhibit 37: Global immunotherapy drugs market; YoY revenue and growth rate based on type of immunotherapy 2015-2020 ($ billions)
Exhibit 38: Global immunotherapy drugs market segmentation by therapy area
Exhibit 39: Segmentation of global immunotherapy drugs market by therapy area 2015
Exhibit 40: Segmentation of global immunotherapy drugs market by geography 2015
Exhibit 41: Global immunotherapy drugs market revenue by geography 2015-2020 ($ billions)
Exhibit 42: Immunotherapy drugs market in Americas 2015-2020 ($ billions)
Exhibit 43: Market share in the Americas by type of immunotherapy 2015
Exhibit 44: Immunotherapy drugs market in EMEA 2015-2020 ($ billions)
Exhibit 45: Market share in Europe by type of immunotherapy 2015
Exhibit 46: Immunotherapy drugs market in APAC 2015-2020 ($ billions)
Exhibit 47: Market share in APAC by type of immunotherapy 2015
Exhibit 48: Global immunotherapy drugs market: YoY revenue and growth based on geography 2015-2020 ($ billions)
Exhibit 49: Global incidence of cancers 2015 and 2020
Exhibit 50: Population aged 60 years and over: World, developed, and developing regions (millions)
Exhibit 51: Patient assistance programs for immunotherapy drugs
Exhibit 52: Some pipeline molecules for immunotherapy drugs
Exhibit 53: Impact of drivers
Exhibit 54: Approvals and patent expiries of top-selling immunotherapy drugs
Exhibit 55: Average annual treatment cost per patient for some immunotherapy drugs 2014 ($ millions)
Exhibit 56: Impact of drivers and challenges
Exhibit 57: Expected combination regimen launches in immune-oncology 2015-2020
Exhibit 58: Market share analysis of top vendors
Exhibit 59: Competitive assessment of top 10 immunotherapy drugs 2015 ($ billions)
Exhibit 60: YoY sales comparison of top five immunotherapy drugs 2013-2015 ($ billions)
Exhibit 61: F. Hoffmann-La Roche: Immunotherapy drugs segmentation by revenue 2015
Exhibit 62: F. Hoffmann-La Roche: Top-selling immunotherapy drugs 2015
Exhibit 63: F. Hoffmann-La Roche: YoY revenue and growth rate of MabThera/Rituxan (oncology and immunology indications) 2013-2015 ($ billions)
Exhibit 64: F. Hoffmann-La Roche: YoY revenue and growth rate of MabThera/Rituxan (immunology indications only) 2013-2015 ($ billions)
Exhibit 65: F. Hoffmann-La Roche: YoY revenue and growth rate of Actemra/RoActemra 2013-2015 ($ billions)
Exhibit 66: F. Hoffmann-La Roche: Actemra/RoActemra geographic segmentation by revenue 2015
Exhibit 67: F. Hoffmann-La Roche: YoY revenue and growth rate of Avastin 2012-2015 ($ billions)
Exhibit 68: F. Hoffmann-La Roche: YoY revenue and growth rate of Herceptin 2012-2015 ($ billions)
Exhibit 69: F. Hoffmann-La Roche: YoY revenue and growth rate of Herceptin in US 2013-2015 ($ billions)
Exhibit 70: F. Hoffmann-La Roche: YoY revenue and growth rate of Herceptin in EU 2013-2015 ($ billions)
Exhibit 71: F. Hoffmann-La Roche: YoY revenue and growth rate of Herceptin in Japan 2013-2015 ($ billions)
Exhibit 72: F. Hoffmann-La Roche: YoY revenue and growth rate of Perjeta 2012-2015 ($ billions)
Exhibit 73: F. Hoffmann-La Roche: YoY revenue and growth rate of Kadcyla 2013-2015 ($ billions)
Exhibit 74: F. Hoffmann-La Roche: Key takeaways
Exhibit 75: F. Hoffmann-La Roche: Key takeaways
Exhibit 76: AbbVie: Immunotherapy drugs segmentation by revenue 2015
Exhibit 77: AbbVie: YoY revenue and growth rate of HUMIRA 2013-2015 ($ billions)
Exhibit 78: AbbVie: YoY revenue and growth rate of HUMIRA in US 2013-2015 ($ billions)
Exhibit 79: AbbVie: YoY revenue and growth rate of HUMIRA in ROW 2013-2015 ($ billions)
Exhibit 80: AbbVie: Sales of HUMIRA in major markets 2015
Exhibit 81: AbbVie: Key takeaways
Exhibit 82: Johnson & Johnson: Top-selling immunotherapy drugs segmentation by revenue 2015
Exhibit 83: Johnson & Johnson: Top-selling immunotherapy drugs 2015
Exhibit 84: Johnson & Johnson: YoY revenue and growth rate of Remicade 2012-2015 ($ billions)
Exhibit 85: Johnson & Johnson: YoY revenue and growth rate of Stelara 2012-2015 ($ billions)
Exhibit 86: Johnson & Johnson: YoY revenue and growth rate of Stelara in US 2012-2015 ($ billions)
Exhibit 87: Johnson & Johnson: YoY revenue and growth rate of Stelara in ROW 2012-2015 ($ millions)
Exhibit 88: Johnson & Johnson: YoY revenue and growth rate of Simponi/Simponi Aria 2012-2015 ($ billions)
Exhibit 89: Johnson & Johnson: YoY revenue and growth rate of Simponi/Simponi Aria in the US 2012-2015 ($ billions)
Exhibit 90: Johnson & Johnson: YoY revenue and growth rate of Simponi/Simponi Aria in ROW 2012-2015 ($ billions)
Exhibit 91: Johnson & Johnson: Key takeaways
Exhibit 92: Merck: Business segmentation by revenue 2015
Exhibit 93: Merck: Immunotherapy drugs segmentation by revenue 2015
Exhibit 94: Merck: Top-selling immunotherapy drugs 2015
Exhibit 95: Merck: YoY revenue and growth rate of Gardasil/Gardasil9 2012-2015 ($ billions)
Exhibit 96: Merck: YoY revenue and growth rate of ProQuad/M-M-R II/Varivax 2012-2015 ($ billions)
Exhibit 97: Merck: YoY revenue and growth rate of Zostavax 2012-2015 ($ millions)
Exhibit 98: Merck: YoY revenue and growth rate of Pneumovax 23 2012-2015 ($ millions)
Exhibit 99: Merck: YoY revenue and growth rate of RotaTeq 2012-2015 ($ millions)
Exhibit 100: Merck: Key takeaways
Exhibit 101: Amgen: Top-selling immunotherapy drugs 2015
Exhibit 102: Amgen: YoY revenue and growth rate of Enbrel in US and Canada 2012-2015 ($ billions)
Exhibit 103: Amgen: YoY revenue and growth rate of Enbrel in US 2012-2015 ($ billions)
Exhibit 104: Amgen: YoY revenue and growth rate of Enbrel in Canada 2012-2015 ($ millions)
Exhibit 105: Amgen: YoY revenue and growth rate generated from net product sales of Xgeva 2012-2015 ($ billions)
Exhibit 106: Amgen: YoY revenue and growth rate generated from net product sales of Prolia 2012-2015 ($ billions)
Exhibit 107: Amgen: YoY revenue and growth rate of Vectibix in US 2012-2015 ($ millions)
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Global Immunotherapy Drugs 2016-2020
Web Address: http://www.researchandmarkets.com/reports/3642670/
Office Code: SCH3Q69S

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td>USD 2500</td>
</tr>
<tr>
<td>Electronic (PDF) - 1 - 5 Users:</td>
<td>USD 3000</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License:</td>
<td>USD 4000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td>USD 10000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title:
Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof [ ]
First Name: __________________________
Last Name: __________________________
Email Address: *
Job Title: __________________________
Organisation: __________________________
Address: __________________________
City: __________________________
Postal / Zip Code: __________________________
Country: __________________________
Phone Number: __________________________
Fax Number: __________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World